Prothena Corporation (NASDAQ:PRTA)

CAPS Rating: 1 out of 5

Results 1 - 2 of 2

Recs

0
Member Avatar pchop123 (78.37) Submitted: 4/11/2014 1:52:25 PM : Outperform Start Price: $30.35 PRTA Score: -13.19

definitely has some upside

Recs

4
Member Avatar zzlangerhans (99.74) Submitted: 10/22/2013 5:59:51 PM : Underperform Start Price: $22.16 PRTA Score: -15.60

Prothena has a healthy market cap of 450M despite a very immature pipeline and a questionable therapeutic platform. The company purports to treat amyloidosis and Parkinson's disease with monoclonal antibodies against abnormally folded proteins, but there is no clear evidence that those proteins are the causative agents of disease or simply an irrelevant byproduct. Elan bought the pipeline with their acquisition of Athena Neurosciences in 1996, but it doesn't appear they had much interest in developing it until they spun the division off as Prothena last December. The company quickly went back to the capital markets with a 73M dilutive financing this month, and Janssen sold 2.4M of their own shares alongisde the dilution. Not a major vote of confidence from big pharma. The presence of Baker Brothers with 370K shares tells me that much of the catalyst-free rise from 6 to 21 this year is related to a follower effect. Investors will likely have to wait until 2015 for anything more exciting than phase I safety data.

Results 1 - 2 of 2

Featured Broker Partners


Advertisement